Keep patient safety first
Others find the injection requirement a meaningful barrier to long-term adherence
Now is an exciting time for the treatment of steatotic liver disease, says Seth Sclair, MD, a hepatologist with University Hospitals Digestive Health Institute
This is the window to establish training habits and protein intake before the metabolic demand increases
Similarly, symptoms such as difficulty breathing, significant swelling, or a rash spreading beyond the injection site require immediate medical attention
Despite lagging behind some of its incretin mimetic competitors by lacking large-scale evidence of cardiovascular risk reduction in people with type 2 diabetes, the UK commercial launch of tirzepatide has nevertheless been supercharged, not only by favourable clinical trial data but also by a supply chain that has so far proven robust while competitor incretin mimetics have been intermittently unavailable